Stereotactic Body Radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Stereotactic body radiotherapy (SBRT) is an emerging treatment option for liver metastases in patients unsuitable for surgery. We investigated factors associated with clinical outcomes for liver metastases treated with SBRT from a multi-center, international patient registry. Patients with liver metastases treated with SBRT were identified in the RSSearch® Patient Registry. Patient, tumor and treatment characteristics associated with treatment outcomes were assessed. Dose fractionations were normalized to BED10. Overall survival (OS) and local control (LC) were evaluated using Kaplan Meier analysis and log-rank test. The study included 427 patients with 568 liver metastases from 25 academic and community-based centers. Median age was 67 years (31–91 years). Colorectal adenocarcinoma (CRC) was the most common primary cancer. 73% of patients received prior chemotherapy. Median tumor volume was 40 cm3 (1.6–877 cm3), median SBRT dose was 45 Gy (12–60 Gy) delivered in a median of 3 fractions [1–5]. At a median follow-up of 14 months (1–91 months) the median overall survival (OS) was 22 months. Median OS was greater for patients with CRC (27 mo), breast (21 mo) and gynecological (25 mo) metastases compared to lung (10 mo), other gastro-intestinal (GI) (18 mo) and pancreatic (6 mo) primaries (p < 0.0001). Smaller tumor volumes (< 40 cm3) correlated with improved OS (25 months vs 15 months p = 0.0014). BED10 ≥ 100 Gy was also associated with improved OS (27 months vs 15 months p < 0.0001). Local control (LC) was evaluable in 430 liver metastases from 324 patients. Two-year LC rates was better for BED10 ≥ 100 Gy (77.2% vs 59.6%) and the median LC was better for tumors < 40 cm3 (52 vs 39 months). There was no difference in LC based on histology of the primary tumor. In a large, multi-institutional series of patients with liver metastasis treated with SBRT, reasonable LC and OS was observed. OS and LC depended on dose and tumor volume, while OS varied by primary tumor. Future prospective trials on the role of SBRT for liver metastasis from different primaries in the setting of multidisciplinary management including systemic therapy, is warranted. Clinicaltrials.gov: NCT01885299 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Hellman, S., & Weichselbaum, R. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.8 · Cited by 2,562
Cited by
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682
Tsilimigras, D. I., Brodt, P., Clavien, P.-A., Muschel, R. J., D’Angelica, M. I., Endo, I., Parks, R. W., Doyle, M., de Santibañes, E., & Pawlik, T. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00261-6 · Cited by 556
Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications
Bhat, V., Pellizzari, S., Allan, A. L., Wong, E., Lock, M., Brackstone, M., Lohmann, A. E., Cescon, D. W., & Parsyan, A. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103566 · Cited by 31
Metadata
- Authors
- Mahadevan, A., Blanck, O., Lanciano, R., Peddada, A., Sundararaman, S., D’Ambrosio, D., Sharma, S., Perry, D., Kolker, J., & Davis, J.
- Venue
- Radiation Oncology
- Published
- 2018-02-13
- Volume
- 13
- Issue
- 1
- Pages
- 26-26
- ISSN
- 1748-717X (ISSN-L)
- OpenAlex
- W2801291604
- Cited by
- 208
- References
- 2
- FWCI
- 17.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stereotactic Body Radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry. https://app.cochat.ai/papers/10.1186/s13014-018-0969-2
- The paper
- Mahadevan, A., Blanck, O., Lanciano, R., Peddada, A., Sundararaman, S., D’Ambrosio, D., Sharma, S., Perry, D., Kolker, J., & Davis, J. (2018). Stereotactic Body Radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiation Oncology. https://doi.org/10.1186/s13014-018-0969-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.